

Resource Summary Report

Generated by [NIF](#) on Sep 17, 2026

CCRF-SB

RRID:CVCL_1860

Type: Cell Line

Proper Citation

JCRB Cat# IFO50026, RRID:CVCL_1860

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1860

Proper Citation: JCRB Cat# IFO50026, RRID:CVCL_1860

Description: Cell line CCRF-SB is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Childhood T acute lymphoblastic leukemia

Defining Citation: [PMID:62390](#), [PMID:1086134](#), [PMID:3335022](#), [PMID:4363409](#), [PMID:4523807](#), [PMID:4991454](#), [PMID:8316623](#), [PMID:20215515](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26589293](#), [PMID:29892436](#), [PMID:35124168](#), [PMID:35354797](#)

Comments: Population: Caucasian.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: CCRF-SB

Synonyms: CCRF SB, CCRFSB, SB, S.B., GM04154, GM04154B

Cross References: CLO:CLO_0002336, CLO:CLO_0016198, EFO:EFO_0006550, CLDB:cl679, CLDB:cl680, CLDB:cl681, ArrayExpress:E-MTAB-2706, ATCC:CCL-120, BioSample:SAMN03471043, BioSample:SAMN03472769, cancercellines:CVCL_1860, CCRID:4201HUM-CCTCC00304, CCTCC:GDC0304, ChEMBL-Cells:ChEMBL3307643, ChEMBL-Targets:ChEMBL614542, Coriell:GM04154, Cosmic:683533, Cosmic:2301562, Cosmic:2649231, ECACC:89090405, EGA:EGAS00001000610, GEO:GSM5137709, IARC_TP53:21219, IGRhCellID:CCRFSB, IZSLER:BS TCL 12, JCRB:IFO50026, JCRB:JCRB0032, LINCX_LDP:LCL-1006, NCI-DTP:CCRF-SB, PharmacDB:CCRFSB_191_2019, PRIDE:PXD023662, Progenetix:CVCL_1860,

PubChem_Cell_line:CVCL_1860, Wikidata:Q54809040

ID: CVCL_1860

Vendor: JCRB

Catalog Number: IFO50026

Record Creation Time: 20220427T215446+0000

Record Last Update: 20260913T002322+0000

Ratings and Alerts

No rating or validation information has been found for CCRF-SB.

No alerts have been found for CCRF-SB.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 1 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Lee S, et al. (2024) B7H6 is the predominant activating ligand driving natural killer cell-mediated killing in patients with liquid tumours: evidence from clinical, in silico, in vitro, and in vivo studies. EBioMedicine, 110, 105459.